GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apellis Pharmaceuticals Inc (FRA:1JK) » Definitions » Cyclically Adjusted Price-to-FCF

Apellis Pharmaceuticals (FRA:1JK) Cyclically Adjusted Price-to-FCF : (As of May. 21, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Apellis Pharmaceuticals Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Apellis Pharmaceuticals Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Apellis Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apellis Pharmaceuticals Cyclically Adjusted Price-to-FCF Chart

Apellis Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Apellis Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Apellis Pharmaceuticals's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Apellis Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apellis Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Apellis Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Apellis Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Apellis Pharmaceuticals Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Apellis Pharmaceuticals's Cyclically Adjusted FCF per Share for the fiscal year that ended in Dec23 is calculated as:

For example, Apellis Pharmaceuticals's adjusted Free Cash Flow per Share data for the fiscal year that ended in Dec23 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec23 (Change)*Current CPI (Dec23)
=-4.601/129.4194*129.4194
=-4.601

Current CPI (Dec23) = 129.4194.

Apellis Pharmaceuticals Annual Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201412 -0.447 99.070 -0.584
201512 -0.957 99.792 -1.241
201612 -1.362 101.863 -1.730
201712 -2.839 104.011 -3.533
201812 -2.121 105.998 -2.590
201912 -3.078 108.420 -3.674
202012 -1.814 109.897 -2.136
202112 -5.915 117.630 -6.508
202212 -4.584 125.222 -4.738
202312 -4.601 129.419 -4.601

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Apellis Pharmaceuticals  (FRA:1JK) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Apellis Pharmaceuticals Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Apellis Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Apellis Pharmaceuticals (FRA:1JK) Business Description

Traded in Other Exchanges
Address
100 Fifth Avenue, Waltham, MA, USA, 02451
Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3 the central protein in the complement cascade.

Apellis Pharmaceuticals (FRA:1JK) Headlines

No Headlines